Graft Versus Host Disease
Conditions
Interventions
cGVHD steroid treatment group:The enrolled patients were treated with first-line treatment according to the guidelines, prednisone 1mg/kg/d ( or equivalent drug ) treatment, and the patient 's blood
Sponsors
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 65 Years
Inclusion criteria
Inclusion criteria: (a) There is no age limit, male or female; (b) After allogeneic transplantation, according to the 2014 NIH standard, newly diagnosed patients with cGVHD or overlap syndrome who need systematic treatment; (c) The underlying disease is stable, without progression and recurrence; (d) No active or chronic infection; (e) Expected survival >3 months.
Exclusion criteria
Exclusion criteria: (a) Progression or recurrence of underlying diseases; (b) Active or chronic infection; (c) Combined with other malignant tumors and under treatment; (e) Serious cardiovascular disease; (f) Donor lymphocytes or car-t cells were infused within the last 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Steroid-Refractory in patients with cGVHD; | — |
Secondary
| Measure | Time frame |
|---|---|
| 12-month NRM;1-year overall survival;overall response rate to hormone therapy;Expression levels of CXCL9 and CCL17; | — |
Countries
China
Contacts
Public ContactChen ting
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Outcome results
None listed